LASA Share Price Performance
₹7.10
-3.84 (-35.10%)
Price ₹7.10
Share Pricen/a
Lasa Supergenerics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
LASA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Lasa Supergenerics Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -6.80
- 5.90%
- -134.53%
- 19.6%
About LASA
- Founded
- 2016
- Employees
- 66
- CEO
- WebsiteView website
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
